ReviewNature reviews. Urology2010
Intermittent androgen suppression for prostate cancer.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.The Journal of clinical investigation · 2023Article
- Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities.Toxicological sciences : an official journal of the Society of Toxicology · 2019Review
- Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level.Biomolecules · 2019Article
- PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer.Journal of molecular biology · 2018Article
- Case: Testicular oligometastasis from prostate cancer - Report of rare isolated recurrence after radiotherapy and intermittent androgen-deprivation therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2018Article
- Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots.Asian journal of urology · 2017Review
- Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.The Journal of urology · 2015Article
- 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.Endocrinology · 2013Article
- [Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].Der Urologe. Ausg. A · 2012Review
- Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression.Cancer research · 2012Article
- Clinical and biological significance of KISS1 expression in prostate cancer.The American journal of pathology · 2012Article
- Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.Advances in urology · 2012Article
- An intermittent approach for cancer chemoprevention.Nature reviews. Cancer · 2011Review
- Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.The AAPS journal · 2011Article
- Differing levels of testosterone and the prostate: a physiological interplay.Nature reviews. Urology · 2011Review
- Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.Nature reviews. Urology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although androgen deprivation therapy (ADT) has been a cornerstone of the management of prostate cancer for more than 50 years, controversy remains regarding its optimum application. Intermittent androgen suppression (IAS) has been researched since the mid-1980s as a way of reducing the adverse effects and cost of continuous androgen suppression. With preclinical evidence suggesting a potential benefit in terms of time to androgen independence, IAS has been the focus of a number of clinical phase II and III trials. Overall, these trials suggest that IAS is neither inferior nor superior to continuous androgen suppression, with respect to time to castration resistance and cancer-specific survival, but has significant advantages in terms of adverse effects, quality of life and cost. A number of unresolved questions remain, however, including how to select patients for therapy, the optimum duration of therapy, when to restart therapy after the off cycle, and how to define progression to castration-resistant disease. Landmark randomized clinical trials comparing IAS to continuous androgen suppression are in progress and will hopefully answer many of these questions. In future, the use of second-line drugs in the off-treatment phase holds potential for delaying disease progression in men on IAS. At present, men with advanced disease who are deemed candidates for ADT should be informed of IAS as a treatment option, considered experimental from an informed consent point of view, but promising based on current evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.